

21 March 2025

ASX ANNOUNCEMENT

Appointment of Director

Today Medical Developments International Limited (ASX: MVP) announced the appointment of Mark Fladrich to the Board, effective April 1st, 2025.

Mark brings a wealth of experience to MVP with over 30 years in the pharmaceutical industry. His extensive background includes senior leadership roles at global companies, where he has demonstrated exceptional commercial, strategic and operational expertise in a broad range of therapy areas, including pain management.

During his executive career, Mark was most recently Chief Commercial Officer of Grunenthal, a mid-sized privately owned German company specialising in pain management. Mark led the commercial organisation, expanding Grunenthal's footprint beyond Europe and Latin America to establish a commercial presence in the US and relaunch an important pain management treatment in that market.

In his 23 years at AstraZeneca, Mark held several senior roles including Vice President Global Strategic Marketing, Country President roles in Germany, Australia and New Zealand and Regional Head of Southern and Western Europe. Prior to joining AstraZeneca, Mark held various roles at Allergan (now part of AbbVie Inc) and Faulding Pharmaceuticals in Australia.

Mark is the Chair of QBiotics, an Australian public unlisted life sciences company, which focuses on biodiscovery from Australian tropical rainforests in oncology and wound healing therapy areas. Mark is also a Board Observer and Strategic Advisor at HealthMatch, a Sydney based digital startup matching patients with clinical trials, and Chair of the Strategic Advisory Board for Atacana, a global pharmaceutical and biotech industry consulting firm.

Mark holds a Bachelor of Pharmacy (University of South Australia), Master of Business Administration (Macquarie University) and is a graduate of the Australian Institute of Company Directors.

The Chair, Gordon Naylor, said: *"Mark brings extensive global commercial experience to the Company. Mark's experience is highly relevant to our continued commercialisation of Pentrox, as well as being complementary to the Board's membership and capabilities. On behalf of my fellow Directors, I welcome Mark to the Company"*.

The Board looks forward to Mark's contributions in guiding the company towards achieving its long-term objectives.

Mr Fladrich said, *"I am excited to join the Company at this stage of its development and look forward to helping realise the potential of the Company."*

~END~

Authorised for release by the Board of Directors.



Enquiries:

Tara Eaton
Company Secretary
+61 (3) 9547 1888

Anita James
Chief Financial Officer
+61 (3) 9547 1888

About Medical Developments International Ltd

MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Pentrox®, a fast-acting trauma & emergency non-opioid pain relief product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defence Forces, Sports Medicine and for analgesia during short surgical procedures such as change of burns dressings, biopsies and dental procedures, as well as in other medical applications.

For personal use only